<DOC>
	<DOCNO>NCT00340678</DOCNO>
	<brief_summary>This investigation randomize , double-blinded , placebo-controlled clinical trial adult diabetic Pima Indians normal urinary albumin excretion ( albumin-to-creatinine ration less 30 mg/g ) microalbuminuria ( albumin-to-creatinine ration = 30-299 mg/g ) test hypothesis blockade renin-angiotensin system angiotensin receptor blocker ( ARB ) losartan prevent attenuate development progression early diabetic nephropathy subject type 2 diabetes mellitus receive standard diabetes care . One hundred seventy subject recruit study , type 2 diabetes least 5 year , serum creatinine concentration less 1.4 mg/dl , evidence non-diabetic renal disease . Ninety-two subject normal urinary albumin excretion baseline 78 microalbuminuria . Subjects albumin excretion group randomize treatment either angiotensin II receptor antagonist , losartan , placebo . Measurements glomerular filtration rate ( GFR ) , renal plasma flow ( RPF ) fractional clearance albumin IgG make initially , one month , 12-month interval baseline thereafter . A kidney biopsy perform six year 111 subject . Morphometric analysis renal biopsy use determine difference glomerular structure treatment group .</brief_summary>
	<brief_title>Renoprotection Early Diabetic Nephropathy Pima Indians</brief_title>
	<detailed_description>This investigation randomize , double-blinded , placebo-controlled clinical trial adult diabetic Pima Indians normal urinary albumin excretion ( albumin-to-creatinine ratio &lt; 30 mg/g ) microalbuminuria ( albumin-to-creatinine ratio = 30-299 mg/g ) test hypothesis blockade renin-angiotensin system angiotensin receptor blocker ( ARB ) losartan prevent attenuate development progression early diabetic nephropathy subject type 2 diabetes mellitus receive standard diabetes care . One hundred seventy subject recruit study , type 2 diabetes least 5 year , serum creatinine concentration &lt; 1.4 mg/dl , evidence non-diabetic renal disease . Ninety-two subject normal urinary albumin excretion baseline 78 microalbuminuria . Subjects albumin excretion group randomize treatment either angiotensin II receptor antagonist , losartan , placebo . Measurements glomerular filtration rate ( GFR ) , renal plasma flow ( RPF ) fractional clearance albumin immunoglobulin G ( IgG ) make initially , one month , 12-month interval baseline thereafter . A kidney biopsy perform six year 111 subject . Morphometric analysis renal biopsy use determine difference glomerular structure treatment group . The major outcome measure decline GFR le equal 60 ml/min half baseline value subject enter study GFR &lt; 120 ml/min . Other measure renoprotection assess , include group difference 1 ) change albumin excretion , 2 ) change serum creatinine concentration , 3 ) glomerular morphology subject outline .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>INCLUSION CRITERIA : Volunteers Gila River Indian Community meet eligibility criterion invite participate . To eligible participation study , subject must meet following criterion : Aged 1865 . Diagnosis type 2 diabetes great equal 5 year . Serum creatinine concentration le 1.4 mg/dl . Serum potassium concentration less equal 5.5 milliequivalent ( mEq ) /L . At least 2 3 weekly screen urinary albumintocreatinine ratio le 300 mg/g . All screening test within 3 month enrollment . Willingness , receive thorough explanation study , participate . EXCLUSION CRITERIA : Subjects exclude follow reason : Clinically significant disorder liver , cardiovascular disease , cerebrovascular disease , peripheral vascular disease , pulmonary disease , renalurinary disorder , gastrointestinal disorder , hematocrit level less equal 30 percent woman less equal 35 percent men . Renovascular malignant hypertension ; uncontrolled hypertension despite treatment three antihypertensive drug ; hypertension treat antihypertensive medicine primary care physician patient refuse adopt blood pressure treatment regimen outline study protocol . Hematuria unknown etiology . Chronic debilitate disorder without treatment would interfere assessment kidney function might reduce chance survival sufficient length time evaluate efficacy treatment . Currently receive drug regimen include : steroid , immunosuppressant , investigational new drug . Pregnancy . Women childbearing potential must negative pregnancy test prior entry every three month study . Evidence inability empty bladder . Hypersensitivity angiotensinconverting enzyme inhibitor ( ACEi ) , ARBs , iodine . Bleeding disorder , since kidney biopsy could perform safely individual . Massive obesity body mass index great equal 45 kg/m ( 2 ) . Nondiabetic renal disease . Conditions likely interfere inform consent compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Angiotensin II Receptor Antagonist</keyword>
	<keyword>Therapeutic Trial</keyword>
	<keyword>Glomerular Filtration Rate</keyword>
	<keyword>Kidney Biopsy</keyword>
	<keyword>Non-Insulin Dependent Diabetes Mellitus</keyword>
</DOC>